• Most Popular
  • Most Shared

STOCKS NEWS EUROPE-Antisoma up on cancer drug data

Mon Jun 1, 2009 5:56am EDT

Stocks

   

Shares in cancer specialist Antisoma (ASM.L) gain 3.5 percent on the back of fresh Phase II data for its AS1411 drug in leukaemia and Phase I data for its As1409 drug in malignant melanoma.

"This could provide a boost to the shares which have been range bound," says Ian Wainwright, managing director, life sciences specialist sales at brokerage Canaccord Adams.

The data was presented at the leading American Society of Clinical Oncology meeting in Orlando, Florida over the weekend.

To see Antisoma's statements click on [ID:nHUgBVZVSa] and [ID:nMKW5918a]

Reuters messaging rm://ben.deighton.thomsonreuters.com@reuters.net


More from Reuters

An image of U.S. President Barack Obama is seen in an exhibition at the Nobel Peace Centre in Oslo December 9, 2009. Two leading international human rights groups gave Obama mixed reviews on his human rights record on Wednesday, a day before he is slated to accept the 2009 Nobel Peace Prize in Oslo. Human Rights Watch and Amnesty International urged Obama to use his acceptance speech on Thursday to renew U.S. leadership on human rights after its position was undermined by abuses committed during the Bush administration's war on terrorism. REUTERS/Chris Helgren

Copenhagen: What of Obama?

President Barack Obama’s decision to attend the climate talks in Copenhagen is said to show the White House is serious about pursuing a deal to curb global warming. What should Obama commit to on climate change? Share your views.  Full Article | Related Story 

    Climate Conference
    A glass of tap water is served at a restaurant in New York June 10, 2009 REUTERS/Shannon Stapleton

    G7 glass half empty

    Recovering from a punishing global recession has forced the world's richest nations to pay dearly, prompting subdued growth prospects and delayed sighs of relief.   Full Article 

    Global markets
    A crown in a file photo. REUTERS/File
    Special Report:

    No longer king of the hill

    When times were good, hedge fund managers could do what they wanted and people still lined up for a piece of the action. What will the post-crash, post-Madoff, post-Galleon hedge fund universe look like?  Full Article 

    Hedge Funds